Montelukast Dorom (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Dorom, is a leukotriene receptor antagonist presented as a tablet for buccal, nasal, cutaneous and dental use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchospasm in patients requiring anti‑inflammatory therapy.

GNH USA supplies Montelukast Dorom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows strict quality standards and provides regulatory‑approved batches to meet global demand.

Montelukast Dorom acts on the leukotriene pathway to control inflammatory airway diseases.

Asthma: reduces bronchoconstriction and airway inflammation, improving symptom control. Allergic rhinitis: alleviates nasal congestion, sneezing and itching by blocking leukotriene effects. Exercise‑induced bronchospasm: prevents airway narrowing triggered by physical activity, allowing better exercise tolerance.

Montelukast Dorom may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nasopharyngitis

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Angioedema or severe allergic reactions - Neuropsychiatric events such as mood changes, depression, or suicidal thoughts

When prescribing Montelukast Dorom, clinicians should consider several precautionary measures to ensure safe use.

Assess asthma control before initiation: confirm that baseline therapy is optimized. Monitor for neuropsychiatric events: watch for mood changes, depression or suicidal thoughts. Use caution in hepatic impairment: adjust therapy if liver function is compromised. Avoid in patients with known hypersensitivity to montelukast or excipients: discontinue if reactions occur. Review concomitant medications for potential interactions: adjust doses as needed. Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast Dorom can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce montelukast exposure, compromising therapeutic effect. - Concurrent use with other leukotriene pathway inhibitors (e.g., zafirlukast): may increase risk of adverse reactions.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may potentiate anticoagulant effect, requiring INR monitoring. - Phenylephrine or other sympathomimetics: may enhance cardiovascular effects, monitor blood pressure. - Selective serotonin reuptake inhibitors: potential increase in neuropsychiatric side effects, observe patient.